United KingdomA London-based startup called Poolbeg Pharma is set to trial an oral drug, POLB 001, in six NHS hospitals. The drug aims to prevent 'cytokine storm,' a severe side effect of cancer immunotherapy that can cause organ damage. The company also mentioned it is developing a GLP-1 weight loss pill.
Bias read (Center): The article reports on a medical development without taking a stance on political issues. It focuses on scientific progress and healthcare innovation, with no indication of ideological framing or bias.
